GGT5 and lung adenocarcinoma: The results indicated that the expression level of GGT5 was significantly elevated in esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), and stomach adenocarcinoma (STAD) (p < 0.05).